John F. Gerecitano
About
John F. Gerecitano is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology.
According to data from OpenAlex, John F. Gerecitano has authored 101 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Genetics, 53 papers in Pathology and Forensic Medicine and 35 papers in Oncology. Recurrent topics in John F. Gerecitano's work include Chronic Lymphocytic Leukemia Research (56 papers), Lymphoma Diagnosis and Treatment (53 papers) and Acute Lymphoblastic Leukemia research (12 papers). John F. Gerecitano is often cited by papers focused on Chronic Lymphocytic Leukemia Research (56 papers), Lymphoma Diagnosis and Treatment (53 papers) and Acute Lymphoblastic Leukemia research (12 papers). John F. Gerecitano collaborates with scholars based in United States, Australia and France. John F. Gerecitano's co-authors include Rod Humerickhouse, Sari H. Enschede, John F. Seymour, Matthew S. Davids, Andrew W. Roberts, William G. Wierda, Owen A. O’Connor, Elisa Cerri, Brad S. Kahl and John M. Pagel and has published in prestigious journals such as Science, New England Journal of Medicine and Journal of Clinical Investigation.
In The Last Decade
John F. Gerecitano
100 papers receiving 5.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| John F. Gerecitano United States | 28 | 2.2k | 1.9k | 1.8k | 1.7k | 1.1k | 101 | 5.4k | ||
| Betsy LaPlant United States | 35 | 1.4k 0.7× | 1.9k 1.0× | 2.1k 1.2× | 1.8k 1.0× | 1.1k 1.0× | 157 | 4.6k | ||
| Matthew S. Davids United States | 42 | 2.2k 1.0× | 1.8k 1.0× | 3.0k 1.7× | 4.0k 2.3× | 1.6k 1.4× | 261 | 6.9k | ||
| Beatríz Bellosillo Spain | 45 | 2.9k 1.3× | 2.3k 1.2× | 2.2k 1.3× | 3.2k 1.8× | 1.3k 1.2× | 231 | 7.6k | ||
| Lothar Bergmann Germany | 39 | 2.1k 0.9× | 1.4k 0.7× | 798 0.5× | 662 0.4× | 1.0k 0.9× | 182 | 4.8k | ||
| Rod Humerickhouse United States | 37 | 3.7k 1.7× | 2.1k 1.1× | 2.1k 1.2× | 3.1k 1.8× | 1.2k 1.0× | 107 | 8.1k | ||
| Thorsten Zenz Germany | 41 | 2.4k 1.1× | 1.4k 0.7× | 2.6k 1.4× | 3.6k 2.0× | 1.9k 1.7× | 166 | 6.5k | ||
| Bruno Quesnel France | 47 | 3.5k 1.6× | 2.6k 1.4× | 1.2k 0.7× | 1.9k 1.1× | 1.6k 1.5× | 202 | 8.1k | ||
| Jeffrey Tyner United States | 46 | 3.3k 1.5× | 1.3k 0.7× | 657 0.4× | 2.1k 1.2× | 1.3k 1.2× | 238 | 7.1k | ||
| Rebecca Elstrom United States | 31 | 1.8k 0.8× | 1.9k 1.0× | 1.8k 1.0× | 813 0.5× | 1.3k 1.2× | 83 | 5.4k | ||
| Chris Pepper United Kingdom | 39 | 2.0k 0.9× | 1.2k 0.6× | 887 0.5× | 1.8k 1.0× | 1.1k 1.0× | 154 | 4.3k |
Countries citing papers authored by John F. Gerecitano
Since
Specialization
Citations
This map shows the geographic impact of John F. Gerecitano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John F. Gerecitano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John F. Gerecitano more than expected).
Fields of papers citing papers by John F. Gerecitano
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by John F. Gerecitano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John F. Gerecitano. The network helps show where John F. Gerecitano may publish in the future.
Co-authorship network of co-authors of John F. Gerecitano
This figure shows the co-authorship network connecting the top 25 collaborators of John F. Gerecitano. A scholar is included among the top collaborators of John F. Gerecitano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John F. Gerecitano. John F. Gerecitano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kumar, Anita, Carla Casulo, Erel Joffe, et al.. (2022). Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design. Leukemia & lymphoma. 63(12). 2889–2896.
2.
Joffe, Erel, Yan Leyfman, Esther Drill, et al.. (2021). Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue. Blood Advances. 5(2). 345–351.
3.
Borchmann, Sven, Erel Joffe, Craig H. Moskowitz, et al.. (2019). Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 133(20). 2121–2129.
4.
Davids, Matthew S., Michael Hallek, William G. Wierda, et al.. (2018). Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clinical Cancer Research. 24(18). 4371–4379.
5.
Batlevi, Connie Lee, Caitlin M. Stewart, Paul A. Hamlin, et al.. (2018). Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.. Journal of Clinical Oncology. 36(15_suppl). 7520–7520.
6.
Kumar, Anita, Andrew D. Zelenetz, Connie Lee Batlevi, et al.. (2018). Initial Results of a Phase II Study of Sequential Chemotherapy and Lenalidomide Followed By Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma. Blood. 132(Supplement 1). 2880–2880.
7.
Seymour, John F., Thomas J. Kipps, Barbara Eichhorst, et al.. (2017). Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. Blood. 130(Suppl_1). LBA–2.
8.
Infante, Jeffrey R., Philippe A. Cassier, John F. Gerecitano, et al.. (2016). A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas. Clinical Cancer Research. 22(23). 5696–5705.
9.
Ni, Ai, John F. Gerecitano, Paul A. Hamlin, et al.. (2016). Incidence of Infectious Complications Associated with Bendamustine and Anti-CD20 Monoclonal Antibody Combination at Memorial Sloan Kettering Cancer Center (MSKCC). Blood. 128(22). 1778–1778.
10.
Roberts, Andrew W., Matthew S. Davids, John M. Pagel, et al.. (2015). Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine. 374(4). 311–322.
11.
Owens, Colette, John F. Gerecitano, Matthew J. Matasar, et al.. (2015). Effect of prednisone and rituximab prephase on early toxicity in older DLBCL patients (pts) receiving RCHOP within a NHL specific comprehensive geriatric assessment (CGA) trial.. Journal of Clinical Oncology. 33(15_suppl). 8571–8571.
12.
Lunning, Matthew A., Jia Ruan, Adam Boruchov, et al.. (2014). A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Phase I results.. Journal of Clinical Oncology. 32(15_suppl). 8582–8582.
13.
Iasonos, Alexia, Mrinal M. Gounder, David R. Spriggs, et al.. (2012). The Impact of Non–Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials. Clinical Cancer Research. 18(19). 5179–5187.
14.
Gerecitano, John F., Carol S. Portlock, Paul A. Hamlin, et al.. (2011). Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non–Hodgkin Lymphoma. Clinical Cancer Research. 17(8). 2493–2501.
15.
Wilson, Wyndham H., Owen A. O’Connor, Myron S. Czuczman, et al.. (2010). Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. The Lancet Oncology. 11(12). 1149–1159.
16.
Gerecitano, John F., Carol S. Portlock, Craig H. Moskowitz, et al.. (2009). Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. British Journal of Haematology. 146(6). 652–655.
17.
Gerecitano, John F. & Owen A. O’Connor. (2008). Novel Small Molecules in the Treatment of Lymphomas. Cancer treatment and research. 131. 413–460.
18.
Gerecitano, John F., C. Portlock, Paul A. Hamlin, et al.. (2008). A phase I study evaluating two dosing schedules of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) in patients with relapsed/refractory indolent and mantle cell lymphomas. Journal of Clinical Oncology. 26(15_suppl). 8512–8512.
19.
Gerecitano, John F., Clarissa Mathias, Rosemarie Mick, et al.. (2003). Homocysteine and Prothrombin Fragment 1+2 Levels in Patients with Veno-Occlusive Disease after Stem Cell Transplantation. Journal of Hematotherapy & Stem Cell Research. 12(2). 215–223.
20.
Kamijo, Ryutaro, et al.. (1994). Mycobacterium bovis Infection of Mice Lacking Receptors for Interferon-γ or for Transcription Factor IRF-1. Journal of Interferon Research. 14(5). 281–282.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Betsy LaPlant Breakdown of academic impact, for papers by Matthew S. Davids Breakdown of academic impact, for papers by Beatríz Bellosillo Breakdown of academic impact, for papers by Lothar Bergmann Breakdown of academic impact, for papers by Rod Humerickhouse Breakdown of academic impact, for papers by Thorsten Zenz Breakdown of academic impact, for papers by Bruno Quesnel Breakdown of academic impact, for papers by Jeffrey Tyner Breakdown of academic impact, for papers by Rebecca Elstrom Breakdown of academic impact, for papers by Chris Pepper